margetuximab
Jump to navigation
Jump to search
Indications
- ERBB2(HER2)-positive advanced breast cancer in conjunction with chemotherapy
Mechanism of action
- chimeric, Fc-engineered, immune-activating anti-ERBB2 IgG1 monoclonal antibody that shares epitope specificity & Fc-independent antiproliferative effects with trastuzumab
- Fc engineering of margetuximab alters 5 amino acids from wild-type IgG1 to increase affinity for activating Fc-gamma receptor CD16A & to decrease affininty for inhibitory Fc-gamma receptor CD32B
- effects proposed to increase activation of innate & adaptive anti-ERBB2 immune responses, relative to trastuzumab[1]
More general terms
References
- ↑ 1.0 1.1 Rugo HS, Im SA, Cardoso F et al Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. A Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online January 22, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33480963 https://jamanetwork.com/journals/jamaoncology/fullarticle/2775599